Yamashita J, Abe M, Ogawa M
Department of Surgery II, Kumamoto University School of Medicine, Kumamoto, Japan.
Oncology. 1998 Dec;55 Suppl 1:17-22. doi: 10.1159/000055255.
There are indications of the possible effects of sex hormones on pancreatic carcinoma. Estrogen receptor (ER) has been demonstrated in pancreatic tumors in experimental animals and in humans and it has been suggested that endocrine manipulation may be effective in the treatment of pancreatic carcinoma. However, it is still controversial whether this lethal cancer can potentially benefit from endocrine therapy. One explanation for the conflicting data on the benefit of hormonal manipulation in the treatment of pancreatic carcinoma may stem from the fact that there is no adequate marker to assess estrogen dependency of the pancreatic tumors. In this article, we review our work on tissue plasminogen activator as a prognostic guide to evaluate the efficacy of hormonal therapy in human pancreatic carcinoma, and also suggest that a selected subgroup of patients with this lethal cancer may have a potential clinical benefit from endocrine therapy, especially medroxyprogesterone acetate treatment.
有迹象表明性激素可能对胰腺癌产生影响。在实验动物和人类的胰腺肿瘤中已证实存在雌激素受体（ER），有人提出内分泌干预可能对胰腺癌治疗有效。然而，这种致命癌症是否能从内分泌治疗中潜在获益仍存在争议。关于激素干预在胰腺癌治疗中获益的相互矛盾的数据，一种解释可能源于没有足够的标志物来评估胰腺肿瘤的雌激素依赖性。在本文中，我们回顾了我们关于组织纤溶酶原激活物作为评估激素疗法治疗人类胰腺癌疗效的预后指标的研究，并且还表明，对于这种致命癌症的特定亚组患者，内分泌治疗，尤其是醋酸甲羟孕酮治疗，可能具有潜在的临床益处。
